secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001104659-25-019498
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics reports Q4 2024 net loss of $39.7M; pipeline milestones on track
--------------------------------------------------------------------------------

- Net loss $39.7M ($0.42 per share) for Q4 2024; cash and equivalents $470.2M as of Dec 31, 2024.
- Completed GRAND CANYON enrollment (175 adults) for sevasemten in Becker; topline data expected Q4 2026.
- Positive Phase 2 CANYON topline results for sevasemten in Becker; plan to discuss FDA filing in H1 2025.
- On track to report CIRRUS-HCM Phase 2 data in Q1 2025 and LYNX/FOX Duchenne data in H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/0001104659-25-019498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925019498/tm257448d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-019498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer